Business Context and Reporting Period
Company: OrthoPediatrics Corp. (Nasdaq: KIDS)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: OrthoPediatrics is a global medical device company exclusively focused on pediatric orthopedics. It designs, develops, and markets implants, instruments, and specialized braces for children, serving three primary categories: trauma and deformity correction, scoliosis, and sports medicine. The company operates a network of over 45 orthotic and prosthetic (O&P) clinics and sells products in over 75 countries.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Net Revenue | $236,348 | $204,727 |
| Gross Profit | $172,661 | $148,598 |
| Gross Margin | 73% | 73% |
| Operating Loss | $(39,238) | $(35,010) |
| Net Loss | $(39,648) | $(37,822) |
| Net Loss Per Share (Basic & Diluted) | $(1.69) | $(1.64) |
| Cash, Cash Equivalents & Restricted Cash | $21,620 | $45,777 |
| Short-term Investments | $41,295 | $25,013 |
| Total Debt (Principal) | $106,010 | $77,483 |
| Accumulated Deficit | $(275,212) | $(235,564) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 15% to $236.3 million, driven by strong performance in Trauma and Deformity (+15%), Scoliosis (+20%), and Orthotic/Prosthetic (O&P) Specialty Bracing. Sports medicine revenue declined 10%.
- Acquisitions: Significant expansion occurred through the acquisition of Boston Brace International, Inc. (Boston O&P) in 2024 and multiple O&P clinics in 2024 and 2025. In 2025, the company also acquired clinics in Ireland, a clubfoot bracing manufacturer in the UK, and a distributor in Brazil.
- Impairment Charges: Intangible asset impairment increased 153% to $4.6 million, primarily due to lower forecasted revenues for the ApiFix product and the decision to exit the Telos regulatory consulting business.
- Restructuring: Restructuring expenses rose 53% to $5.6 million, largely due to the dissolution of the Telos operation and continued staff reductions.
- Debt Structure: In August 2024, the company replaced its MidCap credit facility with a $100 million arrangement with Braidwell LP, consisting of a $50 million term loan (fully drawn by June 2025) and $50 million in convertible notes.
Guidance, Outlook, and Risks
Management Commentary & Outlook: The company expects to continue incurring operating losses in the near term as it invests in product portfolio expansion and consigned inventory. Management anticipates revenue growth driven by new product launches (e.g., 3P Plating Platform, Active Growing Implants) and the integration of acquired O&P clinics. The company maintains a strong balance sheet with $62.9 million in total liquid assets (cash and short-term investments).
Key Risks & Contingencies:
- Profitability: The company has incurred losses since inception and may be unable to achieve or sustain profitability.
- Regulatory: Extensive FDA and international regulations (MDR, UKCA) apply. Failure to comply could result in recalls or suspension of sales.
- Health Emergencies: Pandemics (e.g., RSV, COVID-19) can disrupt elective surgeries, a primary driver of revenue.
- Reimbursement: Changes in third-party payor policies (Medicare, Medicaid, private insurers) could reduce demand.
- Legal Proceedings: An ongoing arbitration with IMED Surgical regarding software ownership (the '377 Patent) remains a contingency, though the lawsuit was dismissed without prejudice in September 2024.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the current cash position ($62.9M) against the operating loss of ~$40M and significant investing outflows ($43.6M) driven by acquisitions and inventory build.
- Debt Covenants: Review the Braidwell Term Loan covenants, specifically the requirement to maintain unrestricted cash equal to at least 25% of the outstanding principal and minimum net product sales targets.
- Intangible Asset Valuation: Assess the assumptions used in the impairment testing for trademarks (ApiFix, MedTech, Orthex) given the recurring charges and the decision to exit the Telos business.
- Acquisition Integration: Monitor the financial performance and integration of the Boston O&P acquisition and subsequent clinic purchases, which significantly altered the revenue mix toward O&P services.
- Inventory Levels: Review the $133.8 million inventory balance, noting that ~65% is held on consignment, and evaluate the adequacy of the $7.7 million excess and obsolete reserve.